Cargando…
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352804/ https://www.ncbi.nlm.nih.gov/pubmed/34148190 http://dx.doi.org/10.1007/s40273-021-01057-y |
| _version_ | 1783736264575418368 |
|---|---|
| author | Pennington, Becky Alshreef, Abualbishr Flight, Laura Metry, Andrew Poku, Edith Hykin, Philip Sivaprasad, Sobha Prevost, A. Toby Vasconcelos, Joana C. Murphy, Caroline Kelly, Joanna Yang, Yit Lotery, Andrew Williams, Michael Brazier, John |
| author_facet | Pennington, Becky Alshreef, Abualbishr Flight, Laura Metry, Andrew Poku, Edith Hykin, Philip Sivaprasad, Sobha Prevost, A. Toby Vasconcelos, Joana C. Murphy, Caroline Kelly, Joanna Yang, Yit Lotery, Andrew Williams, Michael Brazier, John |
| author_sort | Pennington, Becky |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8352804 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83528042021-08-24 Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study Pennington, Becky Alshreef, Abualbishr Flight, Laura Metry, Andrew Poku, Edith Hykin, Philip Sivaprasad, Sobha Prevost, A. Toby Vasconcelos, Joana C. Murphy, Caroline Kelly, Joanna Yang, Yit Lotery, Andrew Williams, Michael Brazier, John Pharmacoeconomics Correction Springer International Publishing 2021-06-19 2021 /pmc/articles/PMC8352804/ /pubmed/34148190 http://dx.doi.org/10.1007/s40273-021-01057-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Pennington, Becky Alshreef, Abualbishr Flight, Laura Metry, Andrew Poku, Edith Hykin, Philip Sivaprasad, Sobha Prevost, A. Toby Vasconcelos, Joana C. Murphy, Caroline Kelly, Joanna Yang, Yit Lotery, Andrew Williams, Michael Brazier, John Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
| title | Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
| title_full | Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
| title_fullStr | Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
| title_full_unstemmed | Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
| title_short | Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
| title_sort | correction to: cost effectiveness of ranibizumab vs aflibercept vs bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the leavo study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352804/ https://www.ncbi.nlm.nih.gov/pubmed/34148190 http://dx.doi.org/10.1007/s40273-021-01057-y |
| work_keys_str_mv | AT penningtonbecky correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT alshreefabualbishr correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT flightlaura correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT metryandrew correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT pokuedith correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT hykinphilip correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT sivaprasadsobha correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT prevostatoby correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT vasconcelosjoanac correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT murphycaroline correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT kellyjoanna correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT yangyit correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT loteryandrew correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT williamsmichael correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT brazierjohn correctiontocosteffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy |